During a congressional hearing on health care oversight, Rep. Alexandria Ocasio-Cortez questioned CVS Health’s business model ...
CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...
By Puyaan Singh Jan 12 (Reuters) - Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO Daniel O'Day said at a major industry ...
CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the pharmacy benefit manager Caremark, will not add Yeztugo, Gilead’s (NASDAQ:GILD) newly approved HIV PrEP, to its ...
The reason? CVS is more diversified—they operate retail pharmacies (9,000 locations), Pharmacy Benefit Management (CVS ...